Omniose, a preclinical biotechnology company, today announced that it has been acquired by AstraZeneca. The acquisition follows a productive three-year exclusive research collaboration with AstraZeneca.

Under the terms of the agreement, Omniose has become a wholly owned subsidiary of AstraZeneca and a part of the Infectious Disease Unit. The acquisition brings Omniose’s proprietary bioconjugation platform and expertise into AstraZeneca, complementing existing capabilities and supporting its preclinical vaccine programs.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.